Abstract
The functions of 2-arachidonoylglycerol (2-AG), the most abundant endocannabinoid found in the brain, remain largely unknown. Here we show that two previously unknown inhibitors of monoacylglycerol lipase, a presynaptic enzyme that hydrolyzes 2-AG, increase 2-AG levels and enhance retrograde signaling from pyramidal neurons to GABAergic terminals in the hippocampus. These results establish a role for 2-AG in synaptic plasticity and point to monoacylglycerol lipase as a possible drug target.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
68,37 €
only 5,70 € per issue
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.


Change history
12 December 2006
Our paper identified 6-methyl-2-p-tolylaminobenzo[d]oxazin-4-one (URB754; Specs) as a monoacylglycerol lipase (MGL) inhibitor that enhances hippocampal depolarization-induced suppression of inhibition (DSI). However, in subsequent tests of non-commercial URB754, we failed to replicate these results, suggesting that a bioactive impurity was present in the commercial material. We have identified this impurity as bis(methylthio)mercurane (Supplementary Results online). Because this compound interacts with multiple targets, we tested another MGL inhibitor, methylarachidonylfluorophosphonate (MAFP), which prolonged DSI (Fig. 1), confirming that monoacylglycerol lipase contributes to the termination of DSI, as others have reported1. Another generation of endocannabinoid metabolism inhibitors is needed to test this hypothesis further.
References
Freund, T.F., Katona, I. & Piomelli, D. Physiol. Rev. 83, 1017–1066 (2003).
Wilson, R.I. & Nicoll, R.A. Nature 410, 588–592 (2001).
Ohno-Shosaku, T., Maejima, T. & Kano, M. Neuron 29, 729–738 (2001).
Wilson, R.I., Kunos, G. & Nicoll, R.A. Neuron 31, 453–462 (2001).
Piomelli, D. Nat. Rev. Neurosci. 4, 873–884 (2003).
Cravatt, B.F. et al. Nature 384, 83–87 (1996).
Dinh, T.P. et al. Proc. Natl. Acad. Sci. USA 99, 10819–10824 (2002).
Kim, J. & Alger, B.E. Nat. Neurosci. 7, 697–698 (2004).
Porter, A.C. et al. J. Pharmacol. Exp. Ther. 301, 1020–1024 (2002).
Huang, C.C., Chen, Y.L., Lo, S.W. & Hsu, K.S. Mol. Pharmacol. 61, 578–585 (2002).
Hohmann, A.G. et al. Nature 435, 1108–1112 (2005).
Kathuria, S. et al. Nat. Med. 9, 76–81 (2003).
Krantz, A. et al. J. Med. Chem. 33, 464–479 (1990).
Hodson, H.F. et al. International patent application PCT WO 00/40247 (2000).
Acknowledgements
We thank N. Hájos for valuable comments and J. Kim for help with cultures. This research was supported by grants from the US National Institute on Drug Abuse and the University of California Discovery Program (D.P.); from Ministero Istruzione Università e Ricerca and University of Urbino 'Carlo Bo' and University of Parma (G.T. and M.M.); and from the Howard Hughes Medical Institute, US National Institutes of Health, European Union Framework Programme 6 and Országos Tudományos Kutatási Alapprogramok (T.F.F).
Author information
Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare competing financial interests: a patent was filed on behalf of D.P., A.D., A.T., M.M. and G.T. by the University of California, Irvine; the University of Urbino and the University of Parma.
Supplementary information
Supplementary Fig. 1
The effect of URB602 on DSI is mediated by CB1 receptors. (PDF 184 kb)
Supplementary Fig. 2
URB602 does not affect depolarization-evoked Ca2+ transients in hippocampal CA1 pyramidal neurons. (PDF 635 kb)
Supplementary Fig. 3
URB754 and URB602 do not inhibit FAAH activity in rat forebrain slice cultures. (PDF 562 kb)
Supplementary Fig. 4
Effects of a high concentration of URB754 (3 μM) on hippocampal DSI. (PDF 1137 kb)
Supplementary Table 1
Kinetic analysis of the effects of URB754 on the activity of recombinant rat brain MGL expressed in HeLa cells. (PDF 38 kb)
Rights and permissions
About this article
Cite this article
Makara, J., Mor, M., Fegley, D. et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8, 1139–1141 (2005). https://doi.org/10.1038/nn1521
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn1521
Further reading
-
Brain activity of anandamide: a rewarding bliss?
Acta Pharmacologica Sinica (2019)
-
Selective axonal and glial distribution of monoacylglycerol lipase immunoreactivity in the superficial spinal dorsal horn of rodents
Brain Structure and Function (2015)
-
Impaired Fear Memory Specificity Associated with Deficient Endocannabinoid-Dependent Long-Term Plasticity
Neuropsychopharmacology (2014)
-
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
Molecular Psychiatry (2013)
-
Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012
Forensic Toxicology (2013)